key: cord-0776913-qtgrih54
authors: Valencia Manrique, Julio; Ghosh, Kuldeep; Boma, Noella
title: Anticardiolipin antibodies and COVID‐19—A case report from America
date: 2020-06-16
journal: J Med Virol
DOI: 10.1002/jmv.26135
sha: 248f0acef34482edc1c385267ade4f8faa9388f9
doc_id: 776913
cord_uid: qtgrih54

In an effort to unravel the pathological mechanism of COVID-19, several reports and studies have been recently conducted in the frontlines around the world. Some initial clues have been obtained, and among them, the concern for clot formation and the idea of an impaired coagulation has strongly increased. We report a case of pulmonary embolism in a COVID-19 patient who tested positive for anticardiolipin antibodies. This article is protected by copyright. All rights reserved.

To the Editor,

The novel coronavirus pandemic has represented a continuous challenge to the world's medical community since first reported in December 2019 until the present day. The atmosphere of uncertainty surrounding coronavirus disease 2019 has prompted an unprecedented effort to produce scientific literature to understand its physiopathology. In such a way, and even when the evidence is still limited, dysregulation in the coagulation has been recognized as a possible critical pathway of the disease, and theories with notable acceptance have been formulated. Among the recently published articles, there are those showing benefit from anticoagulation, some identified an elevated D-dimer as a poor prognosis predictor, and some described thromboembolic events in patients with COVID-19. We present a case of pulmonary embolism (PE) and detected anticardiolipin antibodies (aCL) in a patient with severe COVID-19 pneumonia.

An 82-year-old-male, with a history of hypertension and benign prostatic hyperplasia, walked in the emergency department complaining of 1-week flu-like symptoms and worsening shortness of breath. He appeared distressed, desaturating, and tachypneic. Initial workup was significant for mild leukocytosis with lymphopenia, increased lactate dehydrogenase, procalcitonin and C-reactive protein, and highly elevated D-dimer (39.863 µg/mL), as shown in Table 1 . The chest X-ray revealed dense and mixed alveolar and interstitial infiltrates compatible with pneumonia. COVID-reverse transcription polymerase chain reaction was sent, the patient was admitted for COVID-19 pneumonia with hypoxemic respiratory failure, and was started on hydroxychloroquine, azithromycin, and ceftriaxone, alongside ascorbic acid, zinc, and placed on oxygen. Due to abnormal D-dimer, PE was suspected, and computed tomographyangiogram of chest performed, confirming the bilateral infiltrates and minimal scattered bilateral PE, as marked in Figure 1 

Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acroischemia

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Note multiple small thrombus in the right middle lobe (panel A, white arrow heads) and right upper lobe (panel B, white arrow heads)